Tagged with clinical

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

UK  A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing raised by UK biotechs in 2019 was down on the record year of 2018, but up on 2016 and 2017. Made with Visme Infographic Maker   A longer term perspective…

Czech Republic Darina Hrdličková, chairwoman of the Association of Contract Research Organizations in the Czech Republic (ACRO-CZ), gives an overview of her new priorities and mission since taking over the position in 2018, and how dedicated she is to showcase the strengths of the Czech healthcare system and the advantages of the…

Sweden As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year presence in the Nordic region and the unparalleled advantages of conducting clinical studies in Sweden.   Sweden has many startups…

France These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks, perhaps contributing to erstwhile CEO David Meek’s decision to quit the firm in December 2019. The company’s share price has since plummeted.   Meek’s resignation to join…

Hungary Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over the last decade, and her outlook on the future of the company.   In comparison with Western European countries, Hungary…

China PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the interviews and found the following recurring themes at the top of these executives’ minds.   “Patients” One recurring theme throughout the interviews was a stated commitment to patients. Many of these…

Facts A snapshot of the latest data on the French pharmaceutical industry from industry association LEEM, including market revenues, R&D investments, employment and consumption. Made with Visme Presentation Maker

Hungary Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological treatments in Hungary, the impact of immunotherapy in oncology, and the future objectives of the society.   There needs to…

Czech Republic Czech Republic’s overall pharma market value increased 5 per cent in 2019, while its units produced decreased by 1 per cent.   Made with Visme Presentation Maker   The number of clinical trials conducted in the Czech Republic increased in 2017 and fell to a three-year low in 2018. Made…

Hungary Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving health outcomes and raising life expectancy in the country. Veberic goes on to highlight the affiliate’s strong contribution to Hungary…

Czech Republic Tomáš Dolezal, president of the International Society for Pharmacoeconomics and Outcomes (ISPOR) Czech Regional Chapter and director of the Institute of Health Economics and Technology Assessment (iHETA), gives an overview of the missions and goals of these two institutes and the pivotal role of health technology assessment (HTA) in the…